Joan S. Brugge

The paper shows BRCA-mutant breast cancers respond to PARP inhibitors with immune remodeling, but PD-L1 blockade is ineffective due to spatial separation of PD-L1+ cells and PD-1+ T cells.

The paper identifies pre-existing tumor cells with interferon and inflammatory programs in HGSOC that increase after chemotherapy, suggesting a therapeutic window for intervention.

The paper analyzes copy number alterations in breast epithelial cells from BRCA mutation carriers and wildtype individuals, finding lineage-specific CNAs that mirror cancer genomes.

The paper identifies a WNT7A-FZD5 signaling axis critical for human fallopian tube stem cell self-renewal using single-cell transcriptomics and organoid models.

This study identifies BRCA1-IRIS as a critical isoform for ICL repair, distinct from BRCA1-p220, by interacting with FANCD2 and promoting its ubiquitylation.

The paper compiles protein response data from cancer cell lines to drug perturbations, showing improved drug sensitivity prediction and building a protein-drug connectivity map with an accessible data portal.